About Seprase (FAP)

Seprase (FAP) forms an important target for several possible therapeutic interventions across diverse diseases. At Alfa Cytology, we work with advances in several targeted therapeutic strategies for seprase (FAP) and are making continuous progress in research towards innovative therapies in cancer , fibrotic diseases, and autoimmune disorders. We strive to develop and bring forth therapies that will make a tremendous difference in treatment and outcome in the care of these complex conditions.

Introduction to Seprase (FAP)

Seprase (FAP), sometimes referred to as a serine protease, is overexpressed across myriad types of tumor-associated fibroblasts (CAFs). Rarely, does one find it expressed in placental histology; basic evidence suggests that the overexpression of seprase (FAP) on CAFs renders poor prognosis and plays operative roles in tumorigenesis, progress, and invasion. Hence, seprase (FAP) is considered an exceedingly vital therapeutic target for cancer.

Fig. 1 The summary of the role of fibroblast activation protein (FAP) in tumor tissues. (Shahvali, S., et al. 2023)

The Structure of Seprase (FAP)

Seprase (FAP) is approximately a 97-kDa endopeptidase with unique properties of release at an Xaa-Pro sequence and with post-prolyl dipeptidase activity. The full-length seprase (fap) consists of a polypeptide of 760 amino acids with an intracellular domain of only 4 amino acids, transmembrane of 21 amino acids, and the remaining length comprising a long-range extracellular domain of oriented 735 amino acids. Seprase (FAP) may exist not only as a homodimer but also somewhat in plasma in soluble form.

Fig. 2 Ribbon model of FAP structure. (Fitzgerald, A. A., et al. 2020)

The Function of Seprase (FAP)

Seprase (FAP) is a serine protein hydrolase with postprolyl dipeptidyl peptidase and endopeptidase activity cleaved and activated at the amino-terminal Xaa-Pro sequence. Seprase (FAP) contributes to the degradation of the extracellular matrix; it additionally participates in processes by which cellular fenestration, fibrosis, wound healing, inflammation, or tumor growth occur.

• Seprase (FAP) is not normally present in normal tissues, but is selectively expressed in tissues that are remodeling and in need of repair, and is thought to be a specific marker of (myo)fibroblast activation.
• Seprase (FAP) is highly upregulated in several cancers and can promote tumor cell migration and infiltration through ECM hydrolysis. It is commonly used as a cancer-associated fibroblast marker.
• Seprase (FAP) acts as a membrane-anchored cell surface protein that can also be hydrolyzed by other protein hydrolases into a soluble form present in tissue fluid and plasma.
• Seprase (FAP) alone is inactive, and both the membrane-anchored and soluble forms require homodimerization to be active.

One-Stop Solutions Targeting Seprase (FAP)

At Alfa Cytology, our drug development professionals, supported by a dedicated team of experts, are committed to pioneering innovative therapeutic and diagnostic solutions. Their constant exertions focus on providing seprase (FAP)-targeted interventions for several conditions, thereby boosting modern medicine progress.

Different Therapeutic Disease Areas

Different disease areas in which drug discovery services support and offer a full range of drug development.

We leverage our expertise and high-end equipment to advance the development of various disease diagnostics.

We have a team of professionals specializing in various FAP-targeted drug development platforms and other state-of-the-art techniques.

Contact Us

Recent advances in science have placed seprase (FAP)-targeted therapies ahead of other approaches in the treatment of a host of terrible diseases. Alfa Cytology is a company keen to provide one-stop solutions in seprase (FAP)-targeted drug development. For more information on our services and pricing structure, please do not hesitate to contact us.

For research use only.